Enterprise Value

9.516M

Cash

19.31M

Avg Qtr Burn

-9.03M

Short % of Float

0.05%

Insider Ownership

61.26%

Institutional Own.

0.77%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ryplazim® (plasminogen) Details
Congenital Plasminogen Deficiency (C-PLGD)

Approved

Quarterly sales

LMNL6511 (GPR84 receptor) Details
Non-alcoholic steatohepatitis , Metabolic disorder, Non-Alcoholic Fatty Liver Disease, Idiopathic pulmonary fibrosis

Phase 1

Initiation

Failed

Discontinued

Fezagepras (PBI-4050) Details
Rare diseases, Lung disease

Failed

Discontinued

Fezagepras (PBI-4050) Details
Rare diseases, Rare genetic disease

Failed

Discontinued